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Introduction
In women, breast cancer causes up to 458 000 deaths 
each year, worldwide (http://www.who.int/cancer/
detection/breastcancer). Notwithstanding, since the 
mid-1970s, survival from breast cancer increases in 
particular in women with early stage breast cancer. 
This improvement is attributed to screening and im-
proved treatment of breast cancer (Peto et al., 2012). 
Some of these women will potentially face treat-
ment related side-effects (Geller et al., 2003; Ridner 
et al., 2007). The most disabling side-effect with 
long term impact on quality on life is the develop-
ment of lymphedema (Petrek et al., 1998; Cheifetz 
et al., 2010; Cidon et al., 2011; Fu MR et al., 2012). 
Several studies have examined the incidence of 
breast cancer-related lymphedema (BCRL) in wom-
en treated for breast cancer (Clark et al., 2005; 
 Paskett et al.,2007; Hayes et al., 2008; MacLean et 
al., 2008; Park et al., 2008). The reported incidence 
of BCRL varies between 0% and 73% mainly due to 
differences in measurement techniques and lack of 
a uniform diagnostic criterion (Erickson et al., 
2001). In clinical practice BCRL is diagnosed by 
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Abstract
Aim: Breast cancer-related lymphoedema (BCRL) is a disabling complication developing after breast cancer treat-
ment in a proportion of patients. Its impact on quality of life becomes more substantial as survival after breast 
cancer diagnosis increases. The incidence of BCRL following breast cancer treatment varies due to a lack of 
 uniform definition and measurement criteria. This review aims to determine the prevalence of BCRL following 
axillary lymph node dissection (ALND) as a benchmark to be used in a risk-benefit medical decision whether to 
proceed with ALND or not. The risk of leaving unresected non-sentinel metastatic lymph nodes with a presumed 
inherent risk of local recurrence will be balanced against the risk of BCRL following a potentially unnecessary 
ALND.
Methods: Pubmed and Embase databases were searched for all publications on BCRL in order to estimate its 
 incidence and to decide on the most appropriate measurement method to use in clinical practice. 
Results: 51 articles were identified on BCRL incidence and measurement technique. Most studies measured BCRL 
based on differences in arm circumference (n = 18) or by self-reported symptoms (n = 18). The weighted average 
of BCRL incidence following ALND measured by self-report and circumference method was 28% and 16%, respec-
tively.
Conclusion: The importance of ALND and irradiation as part of the treatment of operable breast carcinoma is well 
established, but its morbidity is less well documented. We argue self-report as the most appropriate method to 
 establish a diagnosis of BCRL. Therefore a 28% risk of finding non-sentinel lymph node metastases in a completion 
ALND will be regarded as the cut-off in a medical decision to proceed with ALND. 
Key words: Breast cancer, lymphoedema, axillary lymph node dissection, definition, incidence, prevalence.
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ance the risk of unresected metastatic non-SLN and 
so the risk of local recurrence against the risk of de-
veloping BCRL.
Therefore the aim of this systematic review is to 
determine the incidence of BCRL following ALND 
using the measurement method most appropriate in 
clinical practice. This incidence will be used as a 
benchmark in a risk-benefit medical decision wheth-
er or not to proceed with ALND. In the risk-benefit 
analysis, the risk of leaving unresected metastatic 
non-SLNs with a presumed inherent risk of local re-
currence will be balanced against this risk of BCRL 
following a potentially unnecessary ALND. 
Methods
Types of studies
All studies reporting incidence of BCRL with a fol-
low-up of at least 12 months were included. A broad 
search strategy without restriction of search criteria 
was used. Prospective and retrospective studies 
were included. In retrospective studies the develop-
ment of BCRL was traced by chart review and/or a 
questionnaire. Studies examining the preventive ef-
fect of an intervention on the development of BCRL 
were excluded. In case of a randomized controlled 
trial, only data from the control arm was retained. 
Subjects
Patients undergoing ALND for breast cancer were 
included. No restrictions were retained regarding 
age, menopausal status, type of breast surgery.
Types of outcome measures
Studies reporting incidence and prevalence of BCRL 
assessed objectively with water displacement 
 method, circumference measurements, bioelectrical 
impedance analyses and opto-electronic volumeter 
(perometer) and subjectively with self-reports were 
included. 
Search strategies for articles on BCRL
Articles were traced using a comprehensive search 
of several electronic databases, including Pubmed 
and Embase and published from January 1990 until 
2013. The MeSH headings and key words used in 
this search included: ‘breast neoplasm’, ‘breast 
 tumour’, ‘breast cancer, ‘sentinel lymph node’, 
 ‘axillary lymph node dissection’, ‘lymphedema’ 
and ‘surgery’. The terms ‘prevalence’, ‘incidence’ 
and ‘epidemiology’ were also included. Only trials 
that included incidence of BCRL were selected and 
objective measurements or by a validated self- 
administered questionnaire (Cidon et al., 2011). 
Volume displacement measurement technique is 
considered as the gold standard in assessing BCRL. 
However this technique can be cumbersome in a 
busy clinical setting. Most series on BCRL there-
fore have used circumferential measurements of the 
upper arm and forearm to diagnose oedema. 
 Compared to the water displacement method, arm 
circumference measurements indicate where the 
swelling is most pronounced (Tengrup et al., 2000).
Risk factors contributing to the development of 
BCRL include axillary lymph node dissection 
(ALND), radiation therapy, high body mass index, 
cellulites and advanced age (Park et al., 2008; Clark 
et al., 2005; Hayes et al., 2008; Soran et al., 2006). 
The most important risk factors for BCRL are 
ALND and radiation therapy of axilla (Petrek et al., 
2001; Erickson et al., 2001; Armer et al., 2003; 
Mortimer et al., 1996). Whilst 23-58% of women 
with breast cancer and radiotherapy of the axilla de-
veloped BCRL, only 5-21% of the patients without 
postoperative irradiation developed lymphedema 
(Erickson et al., 2001).
Over the past years, breast cancer surgery has be-
come less radical. The widely accepted use of the 
sentinel lymph node biopsy (SLNB) (Mansel et al., 
2006; McLaughlin et al., 2008; Mathew et al., 2006) 
was a major step forward in the prevention of 
BCRL. Studies reporting on the performance of 
SLNB revealed that still in 50% of the women un-
dergoing an ALND after a positive SLNB, the sen-
tinel lymph node (SLN) was the only affected lymph 
node (Kim et al., 2006). Moreover two randomized 
trials showed no improvement in disease-free and 
overall survival related to performing additional 
ALND versus no ALND in women with SLN posi-
tive early stage breast cancer (Giuliano et al., 2011; 
Galimberti et al., 2011). Whereas the wide accep-
tance and implementation of the SLNB in clinical 
practice took only a few years, it is not clear to what 
extent the results of the Giuliano trial will cause a 
paradigm shift in the surgical management of the 
axilla. The answer to this will depend on the impact 
that unresected axillary lymph nodes will have on 
local recurrence rates. Nomograms have been de-
veloped calculating the risk of metastatic non-SLN 
to assist decision making with regard to perform an 
ALND. The interpretation of this risk however is 
subdue to a sense of numeracy (quantitative litera-
cy) (de Jonge et al., 2009). Moreover this risk figure 
stands on its own and refers anywhere to a risk-ben-
efit balancing. Clearly a safe strategy for the man-
agement of the axilla following a positive SLNB is 
missing. Until a save strategy following a positive 
SLND has been found it is a valid approach to bal-
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described both the method of measurement of 
BCRL and the corresponding incidence (Fig. 1).
Most studies measured BCRL based on differ-
ences in arm circumference and self-report of vari-
ous arm symptoms. A minority of reports used wa-
ter displacement method, optoelectronic volumetry 
and bioelectrical impedance analysis as measure-
ment method for lymphoedema (Table I). Hence, 
the further discussion is based on the analyses of the 
incidence of BCRL measured by arm circumference 
and self-reports. A second reason is that these two 
methods are used in clinical practice.
There is a wide range of incidences of BCRL (5 
– 39%) between the different studies (Table I). The 
incidence of BCRL varied not only according to the 
measurement method for lymphedema, but varied 
also according to patient characteristics such as type 
of surgery and adjuvant treatment, the length of fol-
low-up period, and the interval between ALND and 
the measurement of BCRL. All studies included had 
a follow-up of at least 12 months. Only four studies 
had a follow-up of less than 24 months. 
The overall weighted average incidence of BCRL 
was 16% (5% up to 33%) for the arm circumference 
method and 28% (11% up to 39%) for the self- 
report method (Table I, Fig. 2). Tables II and III 
summarize a total of 36 reports on BCRL incidence 
based on arm circumference and self-report respec-
tively, following treatment for breast cancer includ-
ing ALND. The studies are a mixture of retro- and 
prospective studies. Most studies were published 
after the year 2000 and included almost nineteen 
thousand patients. 
 analyzed further. Studies that did not mention how 
lymphedema was defined were excluded. Only full 
text articles written in English were selected. Two 
reviewers (MG and EDJ) independently performed 
the selection of articles based on the content of the 
abstract. See appendix for the extensive search 
strategy.
Data extraction and analysis
Studies were divided according to the measurement 
method into the following categories, 1) arm cir-
cumference, 2) water displacement method, 3) self-
reported arm symptoms, 4) bioelectrical impedance 
analysis, 5) optoelectronic volumetry. The inci-
dence of BCRL specific to each method was pre-
sented as the weighted mean of all incidence rates 
reported by the different studies. A policy concern-
ing completion ALND after a positive SLNB will 
be formulated based on the incidence of BCRL for 
the measurement method that is most useful in clin-
ical practice.
Results 
The literature search as described yielded a total of 
466 reports (179 Pubmed - 287 Embase). Further 
selection by title identified 223 articles. Reports 
were screened on the relevance of abstract content 
by two reviewers. This resulted in 100 full text ar-
ticles. From the reference list, new articles were se-
lected and included if they met the inclusion crite-
ria. Finally, we selected a total of 51articles that 
Fig. 1. — Overview of the systematic literature search concerning incidence and prevalence of BCRL
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significant number of studies are retrospective chart 
reviews, have small sample sizes, are single institu-
tional, and the definition of BCRL and/or its mea-
surement varies from study to study (Soran et al., 
2006). Tsai et al. (2009) conducted a meta-analysis 
to examine the association between treatment fac-
tors and lymphoedema secondary to breast cancer. 
The risk ratio of arm lymphoedema was increased 
Discussion
Arm and/or hand lymphoedema is a debilitating 
side-effect from breast cancer treatment with long-
term and chronic negative impact on quality of life. 
The studies of BCRL are relatively recent as initial 
reports only date from the early 2000’s. The litera-
ture on incidence of BCRL remains controversial. A 
Table I. — The number of articles about incidence of BCRL for each measurement method.
Measurement method Number of articles Incidence weighted average (range)
Circumference 18 16% (5-33%)
Self-report 18 28% (11-39%)
Water displacement 10 17% (10-54%)
Perometry 3 18% (10-45%)
Bio-impedance 2 22% (11-33%)
Fig. 2. — Incidence of BCRL assessed by arm circumference measurements and by self-report for the different studies with more than 
12 months of follow-up and the weighted mean incidence.
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BCRL when the impedance ratio was more than 
three standard deviations more than normative data 
(Hayes et al., 2008). This method is very accurate 
and reliable and has been successfully used in the 
estimation of unilateral lymphedema. The method is 
expensive and not suitable for patients with a pace-
maker. Two trials reported on bio-impedance as a 
measuring tool for BCRL and found a mean inci-
dence for BCRL of 22% (11% and 33%). 
It is obvious from this review that the incidence 
of BCRL differs depending on the measurement 
method used. Armer et al. (2009) however demon-
strated a BCRL incidence at 30 months follow-up 
varying between 41% and 91% according to four 
diagnostic criteria: i) 2 cm circumferential change 
at any measured location; ii) 200 ml perometry limb 
volume change; iii) 10% perometry limb volume 
change; iv) self-report of limb heaviness and swell-
ing in the past year. A 2cm circumferential change 
was the most liberal diagnostic criterion (incidence 
91%) and self report the most conservative (inci-
dence 41%).
Consensus on the preferred method of measuring 
lymphoedema is missing as reproducibility of the 
techniques is inconsistent. In defining BCRL, the 
availability of both baseline measurements and of 
contralateral arm measurements are necessary. In 
this way asymmetric measurements found postop-
eratively may be attributed to baseline arm differ-
ences rather than the development of BCRL (Yen et 
al., 2009; Mc Lauglin et al., 2008). It is recommend-
ed that BCRL assessment should begin preopera-
tively with assessment of both arms and should 
 continue at regular intervals (Park et al., 2008).
Furthermore it is remarkable that the mean 
 incidence rates of the two most commonly used 
measurement methods differ notable: 16% (range 
5-33%) for arm circumference and 28% (range 11-
39%) for self-report. Some authors suggested that 
self-reporting signs and symptoms might not be as 
good as using an objective definition of BCRL like 
a 2 cm increase in arm circumference (Engel et al., 
2003). Others have demonstrated that self-reported 
differences in arm size and related symptoms could 
be an early indication of BCRL preceding objective 
signs of lymphedema by several weeks or even 
months (Ridner et al., 2007; Norman et al., 2009). 
Moreover Armer et al. (2003) demonstrated self-
reported arm symptoms such as ‘heaviness in past 
year’ and ‘swelling now’ to be highly predictive of 
a circumferential limb difference of ≥ 2 cm. Objec-
tive measures may not be sensitive enough to pick 
up subtle changes that cause symptoms or may be 
measuring effects that cause no symptoms  (Edwards 
et al., 2000; Tengrup et al., 2000; Geller et al., 
2003). That subjective symptoms do not always 
after mastectomy when compared with lumpecto-
my, axillary dissection compared with no axillary 
dissection, axillary dissection compared with senti-
nel node biopsy, radiation therapy, and positive ax-
illary nodes.
The literature on BCRL shows a number of mea-
surement techniques each with its advantages and 
disadvantages as well as its own incidence of BCRL 
(Table I). Frequently used techniques include cir-
cumferential measures at various points along the 
arm, volumetric measurements using immersion of 
the limb in water, skin tonometry, or self-report of 
BCRL. The most common reported methods to 
measure BCRL were arm circumference measure-
ments and self-report (both 18 studies). Eight of 
18 studies defined BCRL as a difference of ≥ 2 cm 
in arm circumference at a corresponding point be-
tween the affected and non-affected limb. Although 
circumferences appear to be a simple method it is 
difficult to obtain reproducible measurements 
(Armer et al., 2009). Self-report of BCRL may be 
obtained by using a screening questionnaire for 
lymphoedema-related symptoms, such as heavi-
ness, swelling or numbness. Such a questionnaire 
needs to be well-structured and tested on validity 
and has to be presented by a trained interviewer 
(Norman et al., 2010). In some of these self-report 
trials patients also underwent an objective arm mea-
surement showing a good correlation between mea-
sured lymphoedema and subjective complaints on 
the questionnaire (Tengrup et al., 2000; Schrenk et 
al., 2000; Kwan et al., 2002). Penha et al. (2011) 
studied the incidence of BCRL in breast cancer sur-
vivors by subjective and objective methods and 
concluded that self-report was significantly more 
accurate in diagnosing clinically relevant BCRL 
(sensitivity 91%, specificity 89%) than the water 
displacement method (sensitivity 82%, specificity 
73%).
The water displacement method as next most 
common reported method (10 trials) detected BCRL 
in 17% of patients (range 10-54%). This method is 
a cumbersome way of measurement. Moreover it 
does not provide data on localization of the lymph-
edema or the shape of the extremity. Perometry was 
developed to meet the need for a quick, hygienic, 
and accurate method of limb volume measurement. 
More and above the fact that it is expensive, the 
method is not suitable for patients with movement 
restriction of the arm. Three studies measured 
BCRL using perometry and reported a BCRL inci-
dence ranging between 10% and 45%. Finally the 
bio-impedance method uses the impedance of the 
extracellular fluid for each limb calculated accord-
ing to the manufacturer’s software to diagnose 
lymphoedema. Participants were diagnosed with 
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up of breast cancer patients. The difference between 
qualitative and quantitative changes at the arm/ 
shoulder level is a plausible explanation of the 
 difference in incidence of BCRL between the ‘self-
report group’ and ‘arm circumference group’ (Fig. 1). 
From this systematic review we can conclude 
that the mean risk to develop BCRL after ALND is 
28%. This incidence rate is based on self-reporting, 
since this is the most appropriate measurement 
method in clinical practice. We propose to use this 
risk as a risk-benefit tool in the decision-making 
whether to proceed with ALND after a positive 
SLNB or not. In theory it would have been prefera-
ble to include only trials designed to report on 
BCRL incidence instead of prevalence because in-
cidence figures will be marginally higher as women 
who develop BCRL at a certain stage will receive 
treatment to counter symptomatology. In the stud-
ies, it is not always evident to differentiate whether 
data on BCRL are presented as an incidence or a 
prevalence figure. Almost 70% of the reports in-
cluded in this review reported on what we interpret-
ed as ‘incidence’ of BCRL (Table II, Table III).
correlate with objective lymphoedema could be ex-
plained by existing sensory changes in the treated 
arm due to neurological damage caused by axillary 
surgery or radiation treatment in absence of swell-
ing of the arm (Ridner et al., 2007; Penha et al., 
2011). 
Patient’s appreciation of symptoms related to 
lymphoedema is pivotal in diagnosing BCRL as 
they themselves can judge the impact of BCRL on 
quality of life more accurately than anyone else. In 
our opinion this argument is decisive in taking self-
report as the reference method to diagnose BCRL. 
However it is important to subject patients who re-
port arm symptoms to a clinical examination spe-
cifically to exclude a primary shoulder problem (for 
example, referred pain from impingement of rotator 
cuff) that could provoke BCRL-like symptoms. The 
incidence of arm or shoulder dysfunction after 
ALND ranges between 30% and 40% (Bani et al., 
2007; Liljegren et al.,1997; Engel et al., 2003). The 
treatment of BCRL and arm/ shoulder dysfunctions 
differs completely. Health professionals do not al-
ways routinely assess arm morbidity in the follow-
Table II. — Summary of all the reports published since 1990 about the incidence of BCRL assessed by arm 
circumference measurements and a follow-up of more than 12 months (n = 18).
Year Author Definition Study 
design
N (period) FU Incidence (proportion ALND) 
1992 Ball ≥ 3 cm R 50 (1982-’90) 12 mo 6%# (100%)
2001 Herd-Smith > 5% R 1278 (1989-’97) 56 mo 16%# (100%)
2001 Petrek Severe, Moderate, 
Mild
R 263 (1976-’78) 20 yrs 13%∞ (100%)
2002 Haid > 10% 151 (1997-’01) 4 yrs 33%∞ (56%)
2002 Powell > 2 cm R 714 (1982-’95) 72 mo 11%# (86%)
2003 Querci > 5% PVD > 20%, 
PVD change
R 199 35 mo 33%# (100%)
2005 Clark > 5% P 188 (1999-’00) 3 yrs 21%# (100%)
2005 Niwinska 4-6 cm or > 6 cm 
difference
P 174 (1995-’99) 78 mo 10%# (100%)
2006 Mathew > 2 cm R 506 (2000-’02) 2 yrs 12%# (40%)
2008 Nesvold > 10% or ≥ 2 cm CS 263 (1998-’02) 47 mo RM : 20%∞ / BCS : 8% (100%)
2008 Paim > 2 cm CS 96 (2006) 5 yrs SLNB 4% / ALND 29%# (50%)
2008 Mc Lauglin > 2 cm P 936 (1999-’03) 5 yrs SLNB 5% / ALND 16%∞ (36%)
2008 Park > 2 cm R 450 (2003-’04) 24 mo 25%#  (90%) (90%)
2008 Mac-Lean > 2 cm P 337 12 mo 12%∞ (77%) (77%)
2009 Devoogdt > 10% difference P 49 (2004) 3,4 yrs 18%# (100%)
2010 Yang > 1 cm P 191 (2006-’07) 12 mo 12%∞ (33%)
2012 Ozcinar > 2 cm P 218 (2004-’08) 64 mo SLNB 2% / ALND 5%# (63%)
2012 Bevilacqua > 200 ml P 1054 (2001-’02) 5 yrs 30%# (100%)
R : retrospective ; P : prospective ; CS :cross-sectional ; PVD : percentage volume difference ; RM : radical mastectomy ; BCT : 
breast conservative surgery ; SLND : sentinel lymph node dissection ; ALND : axillary lymph node dissection ; # : Incidence ; 
∞ : Prevalence.
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local axillary control is adequate (99%) after omit-
ting ALND in a group of 104 SN negative breast 
cancer patients (Torrenga et al., 2004). Omitting an 
ALND in women with a positive SLNB as suggest-
ed by the results of the randomized studies ACOSOG 
Z0011 and IBCSG 23-01 inevitably raises this fear 
for axillary recurrences due to unresected metastatic 
non-SLN. Delpech et al. (2013) already warned 
against the broadening of the ACOSOG Z0011 se-
lection criteria to omit a ALND as this resulted in a 
worse outcome in a historic group with positive 
SLN. Moreover the MIRROR study has demon-
strated an increased 5-year regional recurrence rate 
in women with micrometastases in the SLN and no 
completion of ALND (Pepels et al., 2012). Never-
theless a randomised clinical trial in older patients 
(65-80 years) with early breast cancer (T1N0) and a 
clinically clear axilla showed no benefit from axil-
lary dissection: at 15 years of follow-up both groups 
showed a comparable distant metastasis rate, over-
all survival, and breast cancer mortality whilst the 
cumulative incidence of axillary disease in the no 
axillary dissection arm was only 6% (Martelli et al., 
2012). 
For this reason and given the limited and rela-
tively immature data on minimally invasive surgery 
in a select group of women with sentinel positive 
early breast cancer, there is no consensus on the 
Morbidity of ALND and SLNB has been com-
pared in two large randomized trials: the ALMA-
NAC trial (Mansel et al., 2006) and the ACOSOG 
Z11 trial (Mc Laughlin et al., 2008). The incidence 
of any side-effect of SLNB followed by ALND was 
70% compared to 25% in the SLNB-only arm 
(p < 0.001). The incidence of BCRL has dropped 
since the introduction of SLNB. Contra-indications 
for SLNB are scarce and include clinically node-
positive breast cancer, neo-adjuvant treatment of 
breast cancer, pregnancy and lactation and inflam-
matory and other T4 breast cancers (Pesce et al., 
2013). A major concern with SLNB during the years 
of introduction in clinical practice was the false 
negative rate associated with the failure to identify 
the ‘affected’ node (Pesce et al., 2013). In the 
NSABP B32 study, patients with a negative SLNB 
were randomized to ALND or no further surgery 
and the false negative rate in the ALND was 9.8% 
(Krag et al., 2007). Differences in tumor location, 
type of biopsy, and number of removed SLNs af-
fected significantly the false-negative rate. Clinical 
rates of axillary recurrence in patients with negative 
SLN after a mean follow-up period of 10 years are 
less than 1%. That is considerably lower than the 
false negative rates seen in the validation studies of 
completion ALND (Veronesi et al., 2010). Others 
have showed that survival is excellent (98%) and 
Table III. — Summary of all the reports published since 1990 on the incidence of BCRL by self-report with a follow-up of more 
than 12 months (n = 18).
Year Author Study design N (period) FU Incidence (proportion ALND)
1992 Ivens R 126 (1990-’91) 4 yrs 24%%# (100%)
1996 Suneson R 362 (1983-’88) 3 yrs 15%%∞ (> 90%)
1996 Mortimer R 1077 (1991) 9.5 yrs 28%#
1997 Liljegren P 381 (1981-’88) 36 mo 11%%# (100%)
1999 Tengrup P 110 (1992) 5 yrs 19%%# (100%)
2000 Schrenk P 70 (1996-’98) 28 mo 14%%∞ (50%)
2002 Kwan R 467 (1993-’97) 2 yrs 12%%∞ (80%) 
2003 Engel P 990 (1996-’98) 5 yrs 38%%∞ (100%)
2003 Geller R 145 (1996-’97) 35 mo 38%# 
2003 Kornblith R 153 (1975-’80) 20 yrs 39%%∞ (100%)
2004 Hinrichs R 105 (1995-’01) 2 yrs 27%%# (100%)
2007 Bani R 742 (2004-’05) 4.3 yrs 32%#
2007 Paskett P 622 (1998-’05) 3 yrs 32%%# (93%)
2009 Yen R 1338 (2005-’07) 4 years ALND 21%#-SLNB 7% (57%)
2010 Gärtner CS 3253 (2005-’06) 1-3 years 38%%∞ (93%)
2010 Kwan P 997 (2006-’07) 20.9 mo 13%%∞ (74%)
2010 Norman P 631 (1999-’01) 5 yrs 35%%# (81%)
2011 Cidon P 127 (2004-’05) 5 yrs 37%%# (100%)
R: retrospective; P: prospective ; CS: cross-sectional; ; #: Incidence; ∞: Prevalence only moderate LE with constant physical 
discomfort without decrease in functional activity was retained.
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safety of abandoning completion of ALND. Further 
research is needed. A medical decision based on a 
risk/benefit analysis between risk of recurrence and 
excess morbidity due to unnecessary ALND seems 
an appropriate intermediate approach before adopt-
ing a generalized strategy of no ALND until proven 
safe. Many nomograms predicting the risk of non-
SLN metastases have been developed from single-
institution retrospective series. It is important to 
perform an internal validation of the nomogram 
prior to implementation. Prevalence of metastatic 
non-SLN differs from one institution to another for 
a number of reasons: tumour diameter inclusion 
cut-off or whether preoperative ultrasound is used 
to filter a ‘clinically’ negative axillary lymph node 
status (Meretoja et al., 2012). It is also possible to 
calculate an individual woman’s risk to acquire 
lymphedema after ALND. A nomogram developed 
to predict the 5-year probability of BCRL showed a 
5-year cumulative incidence of BCRL of 30.3%. In-
dependent risk factors for developing lymphoedema 
were age, body mass index, ipsilateral arm chemo-
therapy infusions, level of ALND, location of radio-
therapy field, development of postoperative seroma, 
infection, and early oedema (Bevilacqua et al., 
2012). Finally it may be clear that there is also a 
need for internal validation of this benchmark risk 
of self-reported lymphoedema. A pragmatic ap-
proach would be to balance the risk of metastatic 
non-SLN against the risk of BCRL when an ALND 
is performed.
In conclusion, we presented a systematic review 
of the literature regarding the incidence of BCRL 
after ALND. We motivated that self-report of BCRL 
is the most clinical relevant method to decide 
whether a women suffers from lymphoedema. We 
agree with other authors (Yen et al., 2009) that self-
report should become the standard in reporting on 
BCRL alone or combined with arm measurement 
like circumference method. The risk of BCRL after 
ALND can be estimated around 30% both accord-
ing to this review of the literature and supported by 
the results of a recently published nomogram 
 (Bevilacqua et al., 2012). This risk of BCRL of 30% 
is the number that we take into account in our 
 decision-making regarding the clinical benefit of 
performing a completion of ALND in cases of a 
positive SLN. This risk/benefit decision-making 
may become obsolete in the future when abandon-
ing ALND is proven to be safe.
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Appendix: Search strategy of BCRL.
Pubmed: (“Breast Neoplasms”[Mesh] OR Breast 
 Neoplasm* OR Breast Cancer*[tiab] OR Breast Tumor* 
OR (Mammary AND (Carcinoma* OR Neoplasm*)) 
OR “Cancer of the Breast” OR “Cancer of Breast” OR 
Breast malignancy*) AND (“Sentinel Lymph Node 
Biopsy”[Mesh] OR “Lymph Node Excision”[Mesh: 
NoExp ] OR Lymphadenectomy* OR Sentinel Node* 
OR (“Axillary Lymph Node” AND (Dissection OR Pro-
cedure* OR Surgery)) OR (“Sentinel Lymph Node” 
AND (Biopsy OR Dissection OR Procedure*)) OR 
(Lymph Node* AND surgical procedure*)) AND 
(“Lymphedema”[Mesh:NoExp] OR Lymphedema* OR 
Lymphoedema*) AND (morbidity OR prevalence OR 
incidence OR disability*) NOT (animals[mh] NOT 
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